+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Chemotherapy Induced Anemia"

From
Chemotherapy-Induced Anemia Market Report 2025 - Product Thumbnail Image

Chemotherapy-Induced Anemia Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Cancer Supportive Care - Global Strategic Business Report - Product Thumbnail Image

Cancer Supportive Care - Global Strategic Business Report

  • Report
  • March 2025
  • 262 Pages
  • Global
From
Cancer Supportive Care Market 2024-2028 - Product Thumbnail Image

Cancer Supportive Care Market 2024-2028

  • Report
  • October 2024
  • 188 Pages
  • Global
From
Chemotherapy Induced Anemia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Anemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Chemotherapy Induced Anemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Chemotherapy Induced Anemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Market Spotlight: Chemotherapy-Induced Anemia - Product Thumbnail Image

Market Spotlight: Chemotherapy-Induced Anemia

  • Report
  • February 2021
  • 32 Pages
  • Global
  • 15 Results (Page 1 of 1)
Loading Indicator

Chemotherapy-induced anemia is a common adverse effect experienced by cancer patients undergoing chemotherapy. Anemia in this context results from the cytotoxic effects of chemotherapy drugs on the bone marrow, which impair red blood cell production. Healthcare services managing chemotherapy-induced anemia include diagnosis, monitoring, and treatment, which involves a multidisciplinary approach. Treatments range from blood transfusions to pharmaceutical interventions that stimulate red blood cell production or manage symptoms. Erythropoiesis-stimulating agents (ESAs) are often used, although their application must be carefully balanced against potential risks, such as thromboembolic events. Intravenous iron supplementation can also be a treatment modality when iron deficiency is identified as a contributing factor. The healthcare service providers closely monitor hemoglobin levels and the overall health status of patients to personalize treatment strategies and optimize patient outcomes while minimizing adverse effects. In the market addressing chemotherapy-induced anemia are several pharmaceutical and biotechnology companies. Among them are Amgen, which produces erythropoietin-stimulating agents, and Johnson & Johnson, with a similar portfolio. Pfizer and Teva Pharmaceutical Industries also offer supportive care products that can be used in the management of chemotherapy-induced anemia. Additionally, companies like Novartis and Roche play active roles in the production of drugs and therapeutic solutions that are part of the broader supportive care arsenal in oncology. Show Less Read more